ANURAS Anupam Rasayan India Q4 FY25 results (Jan–Mar 2025) and concall
Anupam Rasayan demonstrated a strong recovery in Q4 FY25 with robust revenue and EBITDA growth, driven by Pharma and Performance Material segments and a revival in Agrochemicals. Despite a slight full-year revenue decline, the company is optimistic about future growth, supported by new LOIs, capacity expansion, and a focus on deleveraging and working capital efficiency.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 294 | 390 | 500 |
| EBITDA | 80 | 124 | 144 |
| Net profit | 31 | 54 | 63 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
